SCHEMBL2226239

SCHEMBL2226239

CS(=O)(=O)c1ccc(-c2cnc(N)c(-c3cccc(OC(F)(F)F)c3)c2)cc1

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 4/20 0.65
▸ KCNH2 Q12809 3/20 0.65
▸ MINK1 Q8N4C8 2/20 0.65
▸ PIK3CA P42336 1/20 0.65
▸ PI4KB Q9UBF8 1/20 0.65
▸ FYN P06241 6/20 0.58
▸ TNIK Q9UKE5 1/20 0.58
▸ RIPK2 O43353 2/20 0.49
▸ CHEK2 O96017 2/20 0.47
▸ NOD2 Q9HC29 1/20 0.46
▸ PIM1 P11309 2/20 0.46
▸ PIM2 Q9P1W9 2/20 0.46
▸ TGFBR1 P36897 1/20 0.45
▸ ACVR1 Q04771 1/20 0.45
▸ VRK2 Q86Y07 1/20 0.44
▸ CHEK1 O14757 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2225228 0.89 MAP4K4 (0.70) MAP4K4KCNH2MINK1PIK3CAPI4KB
SCHEMBL2227047 0.83 MAP4K4 (0.72) MAP4K4KCNH2MINK1PIK3CAPI4KB
SCHEMBL27885069 0.80 MAP4K4 (0.47) MAP4K4FYNCHEK2TGFBR1ACVR1
SCHEMBL2227291 0.79 MAP4K4 (0.86) MAP4K4KCNH2MINK1PIK3CAPI4KB
SCHEMBL2225090 0.79 FYN (0.77) MAP4K4KCNH2MINK1PIK3CAPI4KB
Mmv-048 SCHEMBL2225969 0.79 KCNH2 (1.00) MAP4K4KCNH2MINK1PIK3CAPI4KB
Mmv-048 SCHEMBL29575216 0.79 KCNH2 (1.00) MAP4K4KCNH2MINK1PIK3CAPI4KB
Mmv-048 SCHEMBL29413286 0.79 KCNH2 (1.00) MAP4K4KCNH2MINK1PIK3CAPI4KB
SCHEMBL4623629 0.78 FYN (0.72) MAP4K4MINK1FYNTNIKCHEK2
SCHEMBL2225148 0.78 MAP4K4 (0.79) MAP4K4KCNH2MINK1PIK3CAPI4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102812006-B Novel antimalaria reagent MMV MEDICINES FOR MALARIA VENTURE (CH) 2016-01-20 — — CN claimed
EP-2526090-B1 NEW ANTI-MALARIAL AGENTS MEDICINES FOR MALARIA VENTURE MMV (CH) 2015-08-19 — — EP claimed
US-9024033-B2 Anti-malarial agents MMV MEDICINES FOR MALARIA VENTURE (CH) 2015-05-05 — — US claimed
CN-102812006-A New anti-malarial agents MEDICINES FOR MALARIA VENTURE MMV 2012-12-05 — — CN claimed
US-20120295905-A1 NEW ANTI-MALARIAL AGENTS MMV MEDICINES FOR MALARIA VENTURE (CH) 2012-11-22 — — US claimed
WO-2011086531-A2 NEW ANTI-MALARIAL AGENTS MMV MEDICINES FOR MALARIA VENTURE (CH) 2011-07-21 — — WO claimed
CN-102812006-B Novel antimalaria reagent MMV MEDICINES FOR MALARIA VENTURE (CH) 2016-01-20 — — CN disclosed
EP-2526090-B1 NEW ANTI-MALARIAL AGENTS MEDICINES FOR MALARIA VENTURE MMV (CH) 2015-08-19 — — EP disclosed
EP-2526090-B1 NEW ANTI-MALARIAL AGENTS MEDICINES FOR MALARIA VENTURE MMV (CH) 2015-08-19 — — EP disclosed
US-9024033-B2 Anti-malarial agents MMV MEDICINES FOR MALARIA VENTURE (CH) 2015-05-05 — — US disclosed
US-9024033-B2 Anti-malarial agents MMV MEDICINES FOR MALARIA VENTURE (CH) 2015-05-05 — — US disclosed
US-9024033-B2 Anti-malarial agents MMV MEDICINES FOR MALARIA VENTURE (CH) 2015-05-05 — — US disclosed
CN-102812006-A New anti-malarial agents MEDICINES FOR MALARIA VENTURE MMV 2012-12-05 — — CN disclosed
US-20120295905-A1 NEW ANTI-MALARIAL AGENTS MMV MEDICINES FOR MALARIA VENTURE (CH) 2012-11-22 — — US disclosed
US-20120295905-A1 NEW ANTI-MALARIAL AGENTS MMV MEDICINES FOR MALARIA VENTURE (CH) 2012-11-22 — — US disclosed
WO-2011086531-A2 NEW ANTI-MALARIAL AGENTS MMV MEDICINES FOR MALARIA VENTURE (CH) 2011-07-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295905-A1 NEW ANTI-MALARIAL AGENTS QDPR, DHFR, ITPA MAP4K4 1556/4885KCNH2 1101/4885MINK1 1827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback